A Phase III Randomized Double Masked Placebo Controlled Multicenter Study to Evaluate the Effica
Research payments
$786,994
Through program year 2025, $786,994 in research payments was reported against A Phase III Randomized Double Masked Placebo Controlled Multicenter Study to Evaluate the Effica, across 73 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $610,646 | 61 |
| 2024 | Research | $176,348 | 12 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jordan Hollsten San Antonio, TX Named on 19 payments
- Matthew Paul Danbury, CT Named on 14 payments
- Cesar Briceno Philadelphia, PA Named on 8 payments
- Louise Mawn Nashville, TN Named on 5 payments
- Ann Tran Chicago, IL Named on 5 payments
- Grant Su Springfield, IL Named on 4 payments
- Kimberly Cockerham Stockton, CA Named on 3 payments
- Zachary Keenum Dallas, TX Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.